There are always a number of clinical trials underway in New Zealand for people with skin disease. These not only provide valuable information on better ways to treat skin disease, but also can give doctors and patients in New Zealand access to newer treatments that we might otherwise not get for many years due to limited funding.
The following is a list of trials that are underway at dermatology trial centres. If you are a patient or a doctor wanting to find out more about a trial, please contact the trial centres directly.
Trials for patients with Eczema
- Trex.Bio. A phase 1b randomized, double-blind, placeobo-controlled, 3-part study to investigate the safety, pharmacokinetics,
and pharmacodynamics of single and multiple subcutaneous doses of a new product targeting T regulatory cell function for
eczema in adults with moderate-to-severe atopic dermatitis. Recruiting now.
Clinical Trials New Zealand (HAMILTON)
Contact email: info@clinicaltrialsnz.com telephone: 07 843 0105
- Nektar. A phase 3, randomized, double-blind, parallel group, placeobo-controlled study to evaluate the efficacy and safety of a new IL-2 agonist for patients ≥ 12 Years of age with moderate-to-severe atopic dermatitis. Recruiting now.
Clinical Trials New Zealand (HAMILTON)
Contact email: info@clinicaltrialsnz.com telephone: 07 843 0105
- Inmagene. A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to
evaluate the efficacy and safety of a new monoclonal antibody targeting OX40 for eczema in adults with moderate-to-severe
atopic dermatitis. Recruiting now.
Clinical Trials New Zealand (HAMILTON)
Contact email: info@clinicaltrialsnz.com telephone: 07 843 0105
Dermatology Department, Greenlane Clinical Centre (Epsom, AUCKLAND).
Contact email: susan.francis@tewhatuora.govt.nz telephone: 021 241 9284
4. Prana. A phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the
efficacy and safety of a new product targeting Il-4, Il-13, and TSLP for eczema in adults with moderate-to-severe atopic
dermatitis.
Recruiting now.
Clinical Trials New Zealand (HAMILTON)
Contact email: info@clinicaltrialsnz.com telephone: 07 843 0105
5. ZaiLab. A phase 1b randomised, double blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability,
and pharmacokinetics of an Il13/Il-31 antagonist in adult participants with moderate to severe atopic dermatitis.
Recruiting now.
Aotearoa Clinical Trials, Te Kohinga Ora
Contact email: info@aotearoatrials.nz telephone: 09 270-9758
Toll Free 0800 367 655 (0800 ENROLL)
Trials for patients with Alopecia Areata
- A phase 3 randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of upadacitinib in paediatric subjects with alopecia areata. Recruiting October 2026.
Clinical Trials New Zealand (HAMILTON)
Contact email: info@clinicaltrialsnz.com telephone: 07 843 0105
Dermatology Department, Greenlane Clinical Centre (Epsom, AUCKLAND)
(16 and 17 years olds ONLY)
Contact email: susan.francis@tewhatuora.govt.nz telephone: 021 241 9284
Trials for patients with Vitiligo
- A phase 3, randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety, and tolerability of upadacitinib in paediatric patients with vitiligo. Recruiting soon.
Clinical Trials New Zealand (HAMILTON)
Contact email: info@clinicaltrialsnz.com telephone: 07 843 0105